TY - JOUR
T1 - Versican is crucial for the initiation of cardiovascular lumen development in medaka (Oryzias latipes)
AU - Mittal, Nishant
AU - Yoon, Sung Han
AU - Enomoto, Hirokazu
AU - Hiroshi, Miyama
AU - Shimizu, Atsushi
AU - Kawakami, Atsushi
AU - Fujita, Misato
AU - Watanabe, Hideto
AU - Fukuda, Keiichi
AU - Makino, Shinji
N1 - Funding Information:
We thank Dr. Toshihiro Nagai and Dr. Shinsuke Shibata, for conducting electron microscopic observations, and Collaborative Research Resources, School of Medicine, Keio University, for technical assistance. We also thank NBRP Medaka, National Institute for Basic Biology for their timely technical support and providing us with the hatching enzyme. This study was supported in part by the program for Grant-in Aid for Scientific Research (21390248, 24390248, 16H05305, 25670397, 25293096, and 19590832) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; KEIO Gijuku Academic Development Funds and Keio Kanrinmaru Project, Japan; Grants for International Activities in Life Sciences and Medicine, Keio University Medical Science Fund, Japan; Keio “Design the Future” award; and MEXT Graduate Scholarship.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Versican is an evolutionary conserved extracellular matrix proteoglycan, and versican expression loss in mice results in embryonic lethality owing to cardiovascular defects. However, the in utero development of mammals limits our understanding of the precise role of versican during cardiovascular development. Therefore, the use of evolutionarily distant species that develop ex utero is more suitable for studying the mechanistic basis of versican activity. We performed ENU mutagenesis screening to identify medaka mutants with defects in embryonic cardiovascular development. In this study, we described a recessive point mutation in the versican 3′UTR resulting in reduced versican protein expression. The fully penetrant homozygous mutant showed termination of cardiac development at the linear heart tube stage and exhibited absence of cardiac looping, a constricted outflow tract, and no cardiac jelly. Additionally, progenitor cells did not migrate from the secondary source towards the arterial pole of the linear heart tube, resulting in a constricted outflow tract. Furthermore, mutants lacked blood flow and vascular lumen despite continuous peristaltic heartbeats. These results enhance our understanding of the mechanistic basis of versican in cardiac development, and this mutant represents a novel genetic model to investigate the mechanisms of vascular tubulogenesis.
AB - Versican is an evolutionary conserved extracellular matrix proteoglycan, and versican expression loss in mice results in embryonic lethality owing to cardiovascular defects. However, the in utero development of mammals limits our understanding of the precise role of versican during cardiovascular development. Therefore, the use of evolutionarily distant species that develop ex utero is more suitable for studying the mechanistic basis of versican activity. We performed ENU mutagenesis screening to identify medaka mutants with defects in embryonic cardiovascular development. In this study, we described a recessive point mutation in the versican 3′UTR resulting in reduced versican protein expression. The fully penetrant homozygous mutant showed termination of cardiac development at the linear heart tube stage and exhibited absence of cardiac looping, a constricted outflow tract, and no cardiac jelly. Additionally, progenitor cells did not migrate from the secondary source towards the arterial pole of the linear heart tube, resulting in a constricted outflow tract. Furthermore, mutants lacked blood flow and vascular lumen despite continuous peristaltic heartbeats. These results enhance our understanding of the mechanistic basis of versican in cardiac development, and this mutant represents a novel genetic model to investigate the mechanisms of vascular tubulogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85068235253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068235253&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-45851-3
DO - 10.1038/s41598-019-45851-3
M3 - Article
C2 - 31263118
AN - SCOPUS:85068235253
SN - 2045-2322
VL - 9
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 9475
ER -